Brokerages Anticipate Charles River Laboratories Intl. Inc (NYSE:CRL) to Announce $1.63 EPS

Equities analysts forecast that Charles River Laboratories Intl. Inc (NYSE:CRL) will report earnings per share (EPS) of $1.63 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Charles River Laboratories Intl.’s earnings. The lowest EPS estimate is $1.57 and the highest is $1.71. Charles River Laboratories Intl. reported earnings per share of $1.53 during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.5%. The company is expected to report its next quarterly earnings report on Wednesday, November 6th.

On average, analysts expect that Charles River Laboratories Intl. will report full-year earnings of $6.52 per share for the current year, with EPS estimates ranging from $6.47 to $6.55. For the next year, analysts anticipate that the business will report earnings of $7.42 per share, with EPS estimates ranging from $7.29 to $7.56. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.08. The business had revenue of $657.60 million for the quarter, compared to analysts’ expectations of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.62 EPS.

CRL has been the topic of a number of recent research reports. Svb Leerink initiated coverage on shares of Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating and a $155.00 target price on the stock. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Leerink Swann initiated coverage on shares of Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday, September 9th. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $147.62.

Shares of Charles River Laboratories Intl. stock traded up $0.46 during trading on Friday, reaching $132.25. The company’s stock had a trading volume of 496,775 shares, compared to its average volume of 252,224. The company has a 50-day moving average price of $131.81 and a two-hundred day moving average price of $136.21. The firm has a market cap of $6.43 billion, a PE ratio of 21.93, a P/E/G ratio of 1.68 and a beta of 1.09. Charles River Laboratories Intl. has a fifty-two week low of $103.00 and a fifty-two week high of $149.07. The company has a current ratio of 1.59, a quick ratio of 1.38 and a debt-to-equity ratio of 1.47.

In other news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the sale, the insider now owns 19,327 shares of the company’s stock, valued at approximately $2,519,467.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.80% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in CRL. Geode Capital Management LLC boosted its position in shares of Charles River Laboratories Intl. by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 457,529 shares of the medical research company’s stock worth $51,782,000 after buying an additional 28,878 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Charles River Laboratories Intl. by 9.9% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,882 shares of the medical research company’s stock worth $273,000 after buying an additional 170 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Charles River Laboratories Intl. by 9.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,521 shares of the medical research company’s stock valued at $2,690,000 after purchasing an additional 1,540 shares in the last quarter. Alps Advisors Inc. acquired a new stake in shares of Charles River Laboratories Intl. during the 1st quarter valued at $417,000. Finally, Texas Permanent School Fund boosted its holdings in shares of Charles River Laboratories Intl. by 4.0% during the 1st quarter. Texas Permanent School Fund now owns 32,745 shares of the medical research company’s stock valued at $4,756,000 after acquiring an additional 1,272 shares in the last quarter. Institutional investors own 94.40% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.